Enrolled Into BaseLaunch, A Top Swiss BioIncubator in 2017

SunRegen SBC003 project was accepted as a phase I project by BaseLaunch, which is a healthcare accelerator backed by Novartis, Pfizer, Johnson & Johnson, and Roche. (please visit BaseLaunch portfolio.).

SunRegen officially enrolled in BaseLaunch in 2017, marking a major milestone for the SBC003 project. Moreover, BaseLaunch is a leading Swiss bioincubator that supports early-stage healthcare startups. It provides mentorship, funding, and access to a global network of experts. Additionally, top pharmaceutical companies, including Novartis, Pfizer, Johnson & Johnson, and Roche, back the program. This gives startups like SunRegen exposure to industry leaders and potential investors.

Being enrolled into BaseLaunch allowed the SunRegen SBC003 team to receive guidance on regulatory strategy, clinical development, and commercialization of innovative therapies. Furthermore, the program connected the team with other biotech innovators. These connections created opportunities for knowledge sharing, collaboration, and networking. SunRegen strengthened its research capabilities and advanced its mission to develop therapies for neurodegenerative disorders.

As a result, BaseLaunch gave SunRegen access to state-of-the-art laboratory facilities and resources to advance projects efficiently. Experienced mentors helped the team refine scientific strategies, optimize workflows, and align projects with industry standards. Consequently, the SBC003 project progressed effectively while maintaining high-quality research outputs.

Enrollment in BaseLaunch increased SunRegen’s visibility within the European and global healthcare communities. Therefore, the recognition attracted partnerships, collaborations, and funding opportunities. It demonstrated SunRegen’s commitment to innovation, scientific excellence, and translating research into practical therapies.

Through the program, SunRegen advanced the SBC003 project and strengthened its position as a forward-thinking company. In addition, the team continues to benefit from guidance, expertise, and networking opportunities that drive innovation and contribute to progress in regenerative medicine.